Normax (Shanghai) Pharmaceutical Technology Co Ltd

Primary objective: To evaluate the safety and tolerability of single and multiple escalating doses of RMX1001 in healthy Chinese adult subjects Secondary objectives: 1) To determine the major metabolites in human plasma; 2) To evaluate the pharmacokinetic characteristics of RMX1001 and its major metabolites after single and multiple oral administration of different doses of RMX1001 in healthy Chinese adult subjects;

Phase II: Primary purpose: To evaluate the anti-tumor effect of paclitaxel oral solution by objective response rate. Secondary purpose: To evaluate the following: Progression-free survival Overall survival Time to treatment failure Disease control rate Quality of life Safety Phase III: Primary purpose: To compare the progression-free survival between the experimental group and the control group; Secondary purpose: To compare the objective response rate, overall survival, time to treatment failure, disease control rate, quality of life and safety between the experimental group and the control group.

Primary objective: To compare the progression-free survival (PFS) of paclitaxel oral solution (RMX3001/DHP107) and paclitaxel injection (Taxol®) as second-line treatment for patients with advanced gastric cancer. Secondary objective: To compare the overall survival (OS), objective response rate (ORR), disease control rate (DCR), safety, and tolerability of paclitaxel oral solution (RMX3001/DHP107) and paclitaxel injection (Taxol®) as second-line treatment for patients with advanced gastric cancer.